
    
      This is a multicenter, randomized double-blind, placebo-controlled dose-escalation and
      parallel-arm, dose-ranging study. Enrollment is planned to occur at approximately 14 global
      sites. Approximately 24 subjects with CF who are homozygous for the F508del-CFTR mutation
      will be enrolled in two cohorts.
    
  